Item 8.01. Other Events.



On August 17, 2021, BeiGene, Ltd. ("BeiGene") and EUSA Pharma (UK), Ltd.
announced that the China National Medical Products Administration (NMPA) has
granted QARZIBA® (dinutuximab beta) conditional approval for the treatment of
high-risk neuroblastoma in patients aged 12 months and above who have previously
received induction chemotherapy and achieved at least a partial response,
followed by myeloablative therapy and stem cell transplantation, as well as
patients with a history of relapsed or refractory (R/R) neuroblastoma with or
without residual disease. Dinutuximab beta is a targeted immunotherapy approved
by the European Medicines Agency. The full text of this press release is filed
as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit No.            Description

       99.1               Press Release titled "BeiGene and EUSA Pharma

Announce China NMPA Approval of


                          QARZIBA® (Dinutuximab Beta) for Patients with

High-Risk Neuroblastoma",


                          issued by BeiGene, Ltd. on August 17, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL


--------------------------------------------------------------------------------


                                 Exhibit Index

   Exhibit No.            Description

       99.1                 Press Release titled "BeiGene and EUSA Pharma

Announce China NMPA Approval of


                          QARZIBA    ®     (Dinutuximab Beta) for Patients

with High-Risk Neuroblastoma",


                          issued by BeiGene, Ltd. on August 17, 2021.

       104                The cover page from this Current Report on Form

8-K, formatted in Inline XBRL

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses